SUSTAINED RELEASE PEPTIDE FORMULATIONS Russian patent published in 2025 - IPC A61K38/08 A61K9/08 A61K47/24 A61K47/14 A61K47/10 A61P3/04 

FIELD: medicine; pharmaceutics.

SUBSTANCE: present invention discloses, at least partially, a pharmaceutical product containing: setmelanotide (also known as RM493); setmelanotide as the only active pharmaceutical ingredient formulated for injection; setmelanotide as the only active ingredient; setmelanotide as an active pharmaceutical ingredient; setmelanotide as an active pharmaceutical ingredient for injection or another pharmaceutical composition, which is characterized by a primary mechanism of action on the MC4 receptor as an agonist (referred to herein as MC4RA_P), for example, an adjuvant, which is a lipid, and/or a pharmaceutically acceptable carrier.

EFFECT: pharmaceutical product described in this document provides a prolonged release of setmelanotide or another pharmaceutical composition, which can lead to a more desirable pharmacokinetic and pharmacodynamic profile when administered.

53 cl, 9 dwg, 5 tbl, 3 ex